Pharmacokinetics of linezolid in septic patients with and without extended dialysis

European Journal of Clinical Pharmacology

Volumn 66, Issue 3, 2010, Pages 291-298

  Swoboda, Stefanie ^a   Ober, Michael C ^a   Lichtenstern, Christoph ^a   Saleh, Soundos ^b   Schwenger, Vedat ^a   Sonntag, Hans Günther ^c   Haefeli, Walter Emil ^a   Hempel, Georg ^b   Hoppe Tichy, Torsten ^a   Weigand, Markus A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Intensive care unit; Linezolid; Methicillinresistant Staphylococcus aureus; Renal replacement therapy; Septic shock; Vancomycin resistant enterococci

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EXTENDED DAILY DIALYSIS; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INTENSIVE CARE UNIT; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; SEPSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG MONITORING; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METHODOLOGY; MIDDLE AGED; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ACETAMIDES; AGED; ANTI-INFECTIVE AGENTS; DRUG MONITORING; FEMALE; HEPATECTOMY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; KIDNEY FAILURE, ACUTE; LIVER TRANSPLANTATION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; OXAZOLIDINONES; RENAL DIALYSIS; SEPSIS; TREATMENT OUTCOME;

EID: 77951926022     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0766-9     Document Type: Article

References (32)

1. Ronco C, Bellomo R, Homel P, Brendolan A, Dan M, Piccinni P, La GG (2000) Effects of different doses in continuous venovenous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26-30
2. Schiffl H, Lang SM, Fischer R (2002) Daily hemodialysis and the outcome of acute renal failure. N Engl J Med 346:305-310 (Pubitemid 34438837)
3. Dhondt AW, Vanholder RC, De Smet RV, Claus SA, Waterloos MA, Glorieux GL, Delanghe JR, Lameire NH (2003) Studies on dialysate mixing in the Genius single-pass batch system for hemodialysis therapy. Kidney Int 63:1540-1547
4. Kumar VA, Craig M, Depner TA, Yeun JY (2000) Extended daily dialysis: A new approach to renal replacement for acute renal failure in the intensive care unit. Am J Kidney Dis 36:294-300
5. Kumar VA, Yeun JY, Depner TA, Don BR (2004) Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report. Int J Artif Organs 27:371-379
6. Marshall MR, Golper TA, Shaver MJ, Alam MG, Chatoth DK (2001) Sustained low-efficiency dialysis for critically ill patients requiring renal replacement therapy. Kidney Int 60:777-785
7. Vanholder R, Van BW, Lameire N (2001) What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephrol 12[Suppl 17]:S40-S43
8. Swoboda S, Fritz S, Martignoni ME, Feldhues RA, Hoppe-Tichy T, Buchler MW, Geiss HK (2005) Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 56:787-789
9. Gonzales RD, Schreckenberger PC, Graham MB, Kalkar S, DenBesten K, Quinn JP (2001) Infections due to vancomycinresistant Enterococcus faecium resistant to linezolid. Lancet 357:1179
10. Wilson P, Andrews JA, Charlesworth R, Walesby R, Singer M, Farrell DJ, Robbins M (2003) Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51:186-188
11. Herrero IA, Issa NC, Patel R (2002) Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 246:867-869
12. Gentry-Nielsen MJ, Olsen KM, Preheim LC (2002) Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother 46:1345-1351
13. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ (2003) Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42:1411-1423
14. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C (2006) Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 50:2455-2463
15. Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65:757-773
16. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29:530-538 (Pubitemid 36523666)
17. Lonnemann G, Floege J, Kliem V, Brunkhorst R, Koch KM (2000) Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system. Nephrol Dial Transplant 15:1189-1193
18. Fassbinder W (1998) Renaissance of the batch method? Nephrol Dial Transplant 13:3010-3012
19. Swoboda S, Ober M, Anagnostakos K, Geiss HK, Weigand MA, Hoppe-Tichy T (2007) A simple isocratic HPLC assay to determine linezolid concentrations in different biomatrices for in vivo and in vitro studies. Clin Chem Lab Med 45:1019-1022
20. Livermore DM (2003) Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 51[Suppl 2]:ii9-ii16
21. Pea F, Viale P, Furlanut M (2005) Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 44:1009-1034
22. Mehrotra R, De GR, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145-2156
23. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Muller M (2001) Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 29:385-391
24. Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129-1140
25. Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De GR, Novelli A (2008) Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 31:122-129
26. Boak LM, Li J, Rayner CR, Nation RL (2007) Pharmacokinetic/ pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrob Agents Chemother 51:1287-1292
27. Mandema JW (1995) Population pharmacokinetics and pharmacodynamics. In: Welling PG, Tse FLS (eds) Pharmacokinetics: regulatory, industrial, academic perspectives, 2nd edn. Marcel Dekker, New York, pp 411-450
28. Meyer B, Kornek GV, Nikfardjam M, Karth GD, Heinz G, Locker GJ, Jaeger W, Thalhammer F (2005) Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration. J Antimicrob Chemother 56:172-179
29. Mauro LS, Peloquin CA, Schmude K, Assaly R, Malhotra D (2006) Clearance of linezolid via continuous venovenous hemodiafiltration. Am J Kidney Dis 47:e83-e86
30. Kraft MD, Pasko DA, DePestel DD, Ellis JJ, Peloquin CA, Mueller BA (2003) Linezolid clearance during continuous venovenous hemodiafiltration: a case report. Pharmacotherapy 23:1071-1075
31. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Manini P, Andreoli R, Cabassi A (2006) Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transplant 21:1402-1406
32. Fiaccadori E, Maggiore U, Rotelli C, Giacosa R, Parenti E, Picetti E, Sagripanti S, Manini P, Andreoli R, Cabassi A (2004) Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 32:2437-2442